Dr. Paul T. Henderson is an Assistant Adjunct Professor in the Department of Internal Medicine / Hematology & Oncology Division at the University of California, Davis Medical Center in Sacramento, CA and a CBST Member. His research interestfocuses on the use of accelerator mass spectrometry to measure small amounts of drugs bound to DNA (DNA adducts), which provides a measure of the cells' propensity to take up the drug, form, and repair DNA damage. These characteristics vary greatly in tumor cells, and Dr. Henderson's laboratory is interested in compiling such information as a means to predict which cancer patients respond to chemotherapy. Research in the Henderson laboratory also focuses on utilization of cell-free protein expression to make nanolipoprotein particles (NLPs), which can be "coexpressed" with membrane proteins such as GPCRs and ERRB2 (HER2).
- Studying how drugs bind to DNA in cells, with the goal of using that information to predict which patients will respond to chemotherapy.
Members of the Henderson Laboratory (co-managed with Dr. Chong-Xian Pan, MD, PhD from UCD):
Dr. Henderson contributes expertise in DNA damage and repair. Dr. Pan provides clinical and research expertise. The Henderson/Pan group has Sisi Wang as a graduate student, Cindy Lin, DVM, PhD as a Postdoctoral Fellow, Hongyong Zhang DVM, PhD as a Research Associate, Yanchun Wang, MD, PhD, a visiting professor from Ji Lin Medical College, and several student volunteers, including Candice Gellner.
2. Hah, S.S.; Stivers, K.M.; de Vere White, R.; Henderson, P.T. Kinetics of Carboplatin-DNA Binding in Genomic DNA and Bladder Cancer Cells As Determined by Accelerator Mass Spectrometry, Chemical Research in Toxicology, 2006, 19, 622-626.
3. Hah, S.S.; Mundt, J.M.; Kim, H.M.; Sumbad, R.A.; Turteltaub, K.W.; Henderson, P.T.Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry, Proceedings of the National Academy of Sciences,USA, 2007, 104, 27, 11203-11208 (cover article).
4. Hah, S.S.; Sumbad, R.A.; de Vere White, R.; Turteltaub, K.W.; Henderson, P.T.Characterization of Oxaliplatin-DNA Adduct Formation in DNA and Differentiation of Cancer Cell Drug Sensitivity at Microdose Concentrations, Chemical Research in Toxicology 2007, 20(12), 1745-1751.
5. Coldwell, K.; Cutts, S.; Henderson, P.T.; Ognibene, T.; Phillips, D. Detection of Adriamycin-DNA adducts by Accelerator Mass Spectroscopy at clinically relevant Adriamycin concentrations Nucleic Acids Research, 2008, 36, 16, e100.
6. Cooke M.S.; Henderson, P.T.; Evans, M.D. Source and significance of extracellular, oxidatively-modified DNA lesions, Journal of Clinical Biochemistry and Nutrition, 2009, 45(3), 255-70.
7. Hah SS, Henderson PT, Turteltaub, KW Recent advances in biomedical applications of accelerator mass spectrometry, Journal of Biomedical Science, 2009, 16, 111.
8. Coldwell K, Cutts SM, Ognibene TJ, Henderson PT, Phillips, DR. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry. Methods Mol. Biol. 2010, 613, 103-18.
9. Microdosing for prediction of patient response. Henderson PT, Pan C-X, Bioanalysis, 2010,In press.
Include skiing, hockey and bicycling.
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis Medical Center, Sacramento, CA 95817
Phone: (925)570-1615 (cell)